- Reuters•9 hours ago
Bristol-Myers Squibb's immunotherapy drug Opdivo has been approved in Europe for the treatment of classical Hodgkin lymphoma, a rare blood cancer, the U.S. company said on Wednesday. Opdivo is already ...
- Business Wire•19 hours agoOpdivo (nivolumab) Alone or Combined With Yervoy (ipilimumab) Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer, From Phase 1/2 Study CheckMate -032
Bristol-Myers Squibb Company announced today updated results for Opdivo monotherapy and in combination with Yervoy in previously treated small cell lung cancer patients, a cohort of the Phase 1/2 open-label CheckMate -032 trial.
BMY : Summary for Bristol-Myers Squibb Company Co - Yahoo Finance
Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Bid||55.81 x 400|
|Ask||56.40 x 100|
|Day's Range||55.56 - 56.04|
|52 Week Range||49.03 - 77.12|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||28.03|
|Dividend & Yield||1.52 (2.72%)|
|1y Target Est||N/A|